Changes in the expression of voltage-gated sodium channels Nav1.3, Nav1.7, Nav1.8, and Nav1.9 in rat trigeminal ganglia following chronic constriction injury

Xu, Wan; Zhang, Jun; Wang, Yuanyin; Wang, Liecheng; Wang, Xuxia

doi:10.1097/wnr.0000000000000632

Cited by 48 publications

(42 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Na v 1.8‐mRNA‐expression on nociceptive, dental primary afferences in trigeminal neurons of rats has been shown as well as a downregulation of Na v 1.8 messenger RNA in trigeminal ganglia following experimental injury (Fig. ) …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia – A New Option? Initial Clinical Case Observations

Kern¹,

Schwickert-Nieswandt²,

Maihöfner

et al. 2019

Headache

View full text Add to dashboard Cite

Background Trigeminal neuralgia is difficult to treat and shows upregulation of sodium channels. The expectorant ambroxol acts as a strong local anesthetic, about 40 times stronger than lidocaine. It preferentially inhibits the channel subtype Nav1.8, expressed especially in nociceptive C‐fibers. It seemed reasonable to try ambroxol for the treatment with neuropathic facial pain unresponsive to other standard options. Material and Methods Medical records of patients suffering from classical trigeminal neuralgia (n = 5) and successful pain reduction following topical ambroxol 20% cream in addition to standard treatment are reported. Results All patients reported pain attacks with pain intensity between 4 and 10 NRS (numeric pain scale). In all cases they could be triggered, 3 patients reported additional spontaneous pain. Attacks were reduced in all 5 patients. Pain reduction achieved following ambroxol 20% cream was 2–8 points (NRS) earliest within 15–30 minutes and lasted for 4–6 hours mostly. This was reproducible in all cases; in one case pain was eliminated after 1 week. No patient reported side effects or skin changes; oral medication was reduced in 2 patients. Conclusion For the first time, a clinically significant pain relief following topical ambroxol 20% cream in patients with trigeminal neuralgia is reported. In view of the positive side effect profile, topical ambroxol for patients with such a highly impaired quality of life should be investigated further as a matter of urgency.

show abstract

Section: Discussionmentioning

confidence: 99%

“…2). 39 Ambroxol and Allodynia.-Triggered pain paroxysms of trigeminal neuralgia resemble allodynia in other conditions of neuropathic pain but there are important differences. Unlike allodynia, trigger zones and pain sensation may be dissociated, a sign of cross-excitation between somatosensory afferents.…”

Section: Discussionmentioning

confidence: 99%

Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia – A New Option? Initial Clinical Case Observations

Kern¹,

Schwickert-Nieswandt²,

Maihöfner

et al. 2019

Headache

View full text Add to dashboard Cite

show abstract

“…Nav1.3 upregulation was reported during peripheral nerve injury, such as spinal nerve ligation, sciatic nerve transection or chronic constriction [69][70][71][72]. In chronic constriction injury of trigeminal ganglia neurons, only Nav1.3 is upregulated at both the mRNA and protein levels, indicating a pivotal role of Nav1.3 in developing trigeminal neuralgia (TN) [73]. Dysregulation of voltagegated Na + channels causes spontaneous neural activity and ectopic discharges, which are thought to be important for neuropathic pain development.…”

Section: Nav13mentioning

confidence: 99%

Pathophysiological roles and therapeutic potential of voltage-gated ion channels (VGICs) in pain associated with herpesvirus infection

Zhang

Martin‐Caraballo

2020

Cell Biosci

View full text Add to dashboard Cite

Herpesvirus is ranked as one of the grand old members of all pathogens. Of all the viruses in the superfamily, Herpes simplex virus type 1 (HSV-1) is considered as a model virus for a variety of reasons. In a permissive non-neuronal cell culture, HSV-1 concludes the entire life cycle in approximately 18-20 h, encoding approximately 90 unique transcriptional units. In latency, the robust viral gene expression is suppressed in neurons by a group of noncoding RNA. Historically the lesions caused by the virus can date back to centuries ago. As a neurotropic pathogen, HSV-1 is associated with painful oral lesions, severe keratitis and lethal encephalitis. Transmission of pain signals is dependent on the generation and propagation of action potential in sensory neurons. T-type Ca 2+ channels serve as a preamplifier of action potential generation. Voltage-gated Na + channels are the main components for action potential production. This review summarizes not only the voltage-gated ion channels in neuropathic disorders but also provides the new insights into HSV-1 induced pain.

show abstract

“…15 Genetic and molecular expression aberrations in patients with TN have been reported. 16 Not all patients with NVC of CN V express the phenotype of the disease and not all patients with TN have NVC. 16 Therefore, it would be reasonable to postulate that a similar genetic or molecular expression component applies to NIN and other CN neuralgias.…”

Section: Figmentioning

confidence: 99%

Pain-free and pain-controlled survival after sectioning the nervus intermedius in nervus intermedius neuralgia: a single-institution review

Holste

Hardaway

Raslan³

et al. 2019

Journal of Neurosurgery

View full text Add to dashboard Cite

OBJECTIVE Nervus intermedius neuralgia (NIN) or geniculate neuralgia is a rare facial pain condition consisting of sharp, lancinating pain deep in the ear and can occur alongside trigeminal neuralgia (TN). Studies on the clinical presentation, intraoperative findings, and ultimately postoperative outcomes are extremely limited. The aim of this study was to examine the clinical presentation and surgical findings, and determine pain-free survival after sectioning of the nervus intermedius (NI). METHODS The authors conducted a retrospective chart review and survey of patients who were diagnosed with NIN at one institution and who underwent neurosurgical interventions. Pain-free survival was determined through chart review and phone interviews using a modified facial pain and quality of life questionnaire and represented as Kaplan-Meier curves. RESULTS The authors found 15 patients with NIN who underwent microsurgical intervention performed by two surgeons from 2002 to 2016 at a single institution. Fourteen of these patients underwent sectioning of the NI, and 8 of 14 had concomitant TN. Five patients had visible neurovascular compression (NVC) of the NI by the anterior inferior cerebellar artery in most cases where NVC was found. The most common postoperative complaints were dizziness and vertigo, diplopia, ear fullness, tinnitus, and temporary facial nerve palsy. Thirteen of the 14 patients reportedly experienced pain relief immediately after surgery. The mean length of follow-up was 6.41 years (range 8 months to 14.5 years). Overall recurrence of any pain was 42% (6 of 14), and 4 patients (isolated NIN that received NI sectioning alone) reported their pain was the same or worse than before surgery at longest follow-up. The median pain-free survival was 4.82 years ± 14.85 months. The median pain-controlled survival was 6.22 years ± 15.78 months. CONCLUSIONS In this retrospective review, sectioning of the NI produced no major complications, such as permanent facial weakness or deafness, and was effective for patients when performed in addition to other procedures. After sectioning of the NI, patients experienced 4.8 years pain free and experienced 6.2 years of less pain than before surgery. Alone, sectioning of the NI was not effective. The pathophysiology of NIN is not entirely understood. It appears that neurovascular compression plays only a minor role in the syndrome and there is a high degree of overlap with TN.

show abstract

Changes in the expression of voltage-gated sodium channels Nav1.3, Nav1.7, Nav1.8, and Nav1.9 in rat trigeminal ganglia following chronic constriction injury

Cited by 48 publications

References 24 publications

Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia – A New Option? Initial Clinical Case Observations

Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia – A New Option? Initial Clinical Case Observations

Pathophysiological roles and therapeutic potential of voltage-gated ion channels (VGICs) in pain associated with herpesvirus infection

Pain-free and pain-controlled survival after sectioning the nervus intermedius in nervus intermedius neuralgia: a single-institution review

Contact Info

Product

Resources

About